Chronic mucocutaneous candidiasis
Chapter 1:Certain infectious and parasitic diseases
ICD-10 B45.3 is a billable code used to indicate a diagnosis of chronic mucocutaneous candidiasis.
Chronic mucocutaneous candidiasis (CMC) is a persistent fungal infection characterized by the overgrowth of Candida species, primarily Candida albicans, affecting the skin, nails, and mucous membranes. This condition is often seen in immunocompromised patients, particularly those with underlying endocrine disorders such as diabetes mellitus or those on immunosuppressive therapy. Clinically, CMC presents with symptoms such as white patches in the oral cavity (oral thrush), chronic nail infections, and skin lesions that may be itchy or painful. The diagnosis is typically confirmed through clinical examination and microbiological cultures. Treatment involves the use of antifungal agents, including topical treatments like clotrimazole or systemic therapies such as fluconazole or itraconazole, depending on the severity and extent of the infection. Management of CMC also requires addressing any underlying immunosuppressive conditions to prevent recurrence. Regular follow-up is essential to monitor treatment efficacy and adjust therapy as needed.
Detailed patient history, including immunocompromised status and previous treatments.
Patients with recurrent candidiasis, particularly those with diabetes or on immunosuppressive therapy.
Need for thorough documentation of treatment response and any changes in immunocompromised status.
Clinical photographs of lesions, detailed descriptions of skin findings.
Patients presenting with skin lesions suggestive of candidiasis.
Differentiation from other dermatological conditions that may mimic candidiasis.
Used to confirm diagnosis of candidiasis.
Document the reason for the culture and any previous treatments.
Infectious disease specialists may order this more frequently.
Chronic mucocutaneous candidiasis is a persistent fungal infection caused by Candida species, primarily affecting the skin, nails, and mucous membranes, often seen in immunocompromised patients.
Treatment typically involves antifungal medications, both topical and systemic, depending on the severity of the infection, along with management of any underlying immunocompromised conditions.
